Evidence map›Paper›PMID 41756322›Full record

ReviewFrontiers in oncology2026

Molecular mechanisms and therapies for tumor inhibition through the arginine metabolism pathway.

Yuhang Xu, Mingxin Yu, Yi Zhang, Yiqing Jiang, Haiyan Zhu, Shujuan He, Guohua Yu, Niannian Li, Shuzhen Liu, Bin Liu

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuhang XuWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Mingxin YuWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Yi ZhangWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Yiqing JiangWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Haiyan ZhuWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Shujuan HeWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Guohua YuWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Niannian LiWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Shuzhen LiuWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.
Bin LiuWeifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumors are one of the major diseases leading to human death. Arginine metabolism plays an important role in tumor occurrence and metastasis. Based on the levels of arginine in tumor cells, methods such as recombinant arginine deiminase are used to reduce arginine in order to inhibit tumor growth. However, arginine deprivation therapy has limited efficacy in tumor cells due to increased arginine synthesis, resistance to chemotherapeutic agents, metabolic reprogramming, and the suppression of immune cells in the tumor microenvironment. Meanwhile, with the revelation of many new molecular mechanisms by which arginine controls tumor cell growth, numerous newly designed molecules targeting arginine metabolic pathways for cancer treatment have emerged. In this review, we integrate and analyze the responses of tumor cells and immune cells such as T cells to arginine and strategies for cancer therapy. At the molecular level, we review and discuss the mechanisms of specifically blocking arginine-regulated metabolic reprogramming in cancer cells, the effector factors from pathogenic microorganisms and metabolites from plants in inhibiting cancer cells via arginine metabolism, and arginine tRNA metabolic pathway. Finally, we discuss the mechanisms and case studies of using antineoplastic agents that target arginine metabolic pathways in combination. This review collects and integrates the mechanisms and experiences of treating various cancers through arginine and its metabolic derivatives, providing direct therapy guidance for cancer patients with disordered arginine metabolism in the tumor and immune cells.

Indexed as

arginine deprivationarginine metabolisminhibitortRNA modificationtumor treatment

Identifiers

PMID41756322
PMCPMC12932223

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.